Dierks Jeffrey 4

Accession 0001415889-25-002160

CIK 0001802665other

View on SEC.gov Company Profile

Filed

Jan 27, 7:00 PM ET

Accepted

Jan 28, 4:08 PM ET

Size

24.0 KB

Accession

0001415889-25-002160

Insider Transaction Report

Form 4

Period: 2025-01-24

Harmony Biosciences Holdings, Inc.HRMY

Dierks Jeffrey

CHIEF COMMERCIAL OFFICER

Transactions

Exercise/Conversion
Common Stock
2025-01-24$30.69/sh+13,125$402,806→ 13,125 total
Sale
Common Stock
2025-01-24$36.94/sh−8,000$295,531→ 5,125 total
Sale
Common Stock
2025-01-24$37.87/sh−5,125$194,103→ 0 total
Exercise/Conversion
Common Stock
2025-01-24+2,687→ 2,687 total
Tax Payment
Common Stock
2025-01-24$38.01/sh−1,058$40,215→ 1,629 total
Sale
Common Stock
2025-01-27$38.02/sh−1,629$61,941→ 0 total
Exercise/Conversion
Stock Option
2025-01-24−13,125→ 39,375 total
Exercise: $30.69Exp: 2034-01-24→ Common Stock (13,125 underlying)
Exercise/Conversion
Restricted Stock Units
2025-01-24−2,687→ 8,063 total
→ Common Stock (2,687 underlying)
Award
Stock Option
2025-01-25+47,200→ 47,200 total
Exercise: $38.01Exp: 2035-01-25→ Common Stock (47,200 underlying)
Award
Restricted Stock Units
2025-01-25+13,450→ 13,450 total
→ Common Stock (13,450 underlying)

Footnotes (9)

[F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
[F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.46 to $37.39. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.485 to $38.00. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]Shares withheld by the Issuer to satisfy required income tax withholdings pursuant to the vesting of restricted stock units on their scheduled vesting date.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.78 to $38.40. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F6]The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
[F7]This award of restricted stock units was previously granted on January 24, 2024. The restricted stock units shall vest in four equal annual installments beginning on January 24, 2025, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
[F8]The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.
[F9]The restricted stock units shall vest in four equal annual installments beginning on January 25, 2026, subject to the Reporting Person's continued service through each applicable vesting date. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock and has no expiration date.

Documents

1 file

4
form4-01282025_090140.xmlPrimary

Issuer

Harmony Biosciences Holdings, Inc.

CIK 0001802665

→

Entity typeother

Related Parties

filerCIK 0001821102

Filing Metadata

Form type: 4
Filed: Jan 27, 7:00 PM ET
Accepted: Jan 28, 4:08 PM ET
Size: 24.0 KB

View on SEC.gov